Consistent with the CRC cell line data, BETi treatment reduced phospho-AKT level, increased total p21 protein and reduced the level of phosphorylated p21 at Thr145 in the PDO model (Fig. 7H). The gene discussed is CDKN1A; the disease is colorectal carcinoma.